Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

E. van der Valk, Mirthe; J. Mangen, Marie‐Josée; Leenders, Max; Dijkstra, Gerard; A. van Bodegraven, Ad; H. Fidder, Herma; J. de Jong, Dirk; Pierik, Marieke; Janneke van der Woude, C.; Romberg‐Camps, Mariëlle; H. Clemens, Cees; M. Jansen, Jeroen; Mahmmod, Nofel; C. van de Meeberg, Paul; E. van der Meulen‐de Jong, Andrea; Y. Ponsioen, Cyriel; Bolwerk, Clemens; Vermeijden, J; D. Siersema, Peter; GH van Oijen, Martijn; Oldenburg, Bas; behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis, on

doi:10.1136/gutjnl-2012-303376

Public

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Published in Gut • Nov 7, 2012

Authors:

Mirthe E. van der Valk

Marie‐Josée J. Mangen

Max Leenders

Abstract

OBJECTIVE: The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the introduction of these drugs. We aimed to assess the healthcare costs and productivi...

Subject

Medicine

Inflammatory bowel disease

Health care

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!